JNJ

227.58

-1.32%↓

ABT

91.21

-1.32%↓

MDT

83.38

-0.41%↓

A

115.41

+1%↑

VEEV

160.84

+3.11%↑

JNJ

227.58

-1.32%↓

ABT

91.21

-1.32%↓

MDT

83.38

-0.41%↓

A

115.41

+1%↑

VEEV

160.84

+3.11%↑

JNJ

227.58

-1.32%↓

ABT

91.21

-1.32%↓

MDT

83.38

-0.41%↓

A

115.41

+1%↑

VEEV

160.84

+3.11%↑

JNJ

227.58

-1.32%↓

ABT

91.21

-1.32%↓

MDT

83.38

-0.41%↓

A

115.41

+1%↑

VEEV

160.84

+3.11%↑

JNJ

227.58

-1.32%↓

ABT

91.21

-1.32%↓

MDT

83.38

-0.41%↓

A

115.41

+1%↑

VEEV

160.84

+3.11%↑

Search

Pfizer

Slēgts

SektorsVeselības aprūpe

27 1.47

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

26.97

Max

27.12

Galvenie mērījumi

By Trading Economics

Ienākumi

-5.2B

-1.6B

Pārdošana

903M

18B

P/E

Sektora vidējais

20.235

60.328

EPS

0.66

Dividenžu ienesīgums

6.24

Peļņas marža

-9.387

Darbinieki

75,000

EBITDA

-4.9B

756M

Rekomendācijas

By TipRanks

Rekomendācijas

Pirkt

Prognoze 12 mēnešiem

+10.61% upside

Dividendes

By Dow Jones

Dividenžu ienesīgums

Sektora vidējais

6.24%

2.24%

Nākamie ieņēmumi

2026. g. 5. maijs

Nākamais dividenžu datums

2026. g. 12. jūn.

Nākamais Ex dividenžu datums

2026. g. 8. maijs

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

5B

157B

Iepriekšējā atvēršanas cena

25.53

Iepriekšējā slēgšanas cena

27

Ziņu noskaņojums

By Acuity

54%

46%

141 / 348 Rangs Healthcare

Tehniskais rādītājs

By Trading Central

Pārliecība

Bullish Evidence

Pfizer Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 3. febr. 12:25 UTC

Peļņas

Pfizer Sales Fall on Continued Lower Covid-19 Drug Demand

2026. g. 23. apr. 21:48 UTC

Iegādes, apvienošanās, pārņemšana

Regeneron Shares Up on Trump Drug Pricing Deal -- Barrons.com

2026. g. 1. apr. 20:07 UTC

Iegādes, apvienošanās, pārņemšana

Why 2026 Is Biotech's Comeback Year -- Barrons.com

2026. g. 11. marts 11:02 UTC

Tirgus saruna

Sanofi, Regeneron's Eczema Drug Might Face Competition From Pfizer -- Market Talk

2026. g. 10. marts 12:50 UTC

Peļņas

BioNTech Stock Plunges 17% After Earnings. Why the Drugmaker Faces a Perfect Storm. -- Barrons.com

2026. g. 10. marts 11:18 UTC

Peļņas

BioNTech Plunges as Drugmaker Swings to a Loss. More Than Earnings Are Weighing on the Stock. -- Barrons.com

2026. g. 9. marts 09:43 UTC

Karstas akcijas

Stocks to Watch Monday: Lamb Weston, Carnival, Pfizer -- WSJ

2026. g. 10. febr. 21:51 UTC

Peļņas

Gilead Earnings Surprise. Why The Stock Is Tumbling Anyway. -- Barrons.com

2026. g. 10. febr. 21:17 UTC

Peļņas

Gilead Earnings Surprise. Why The Stock Is Tumbling Anyway. -- Barrons.com

2026. g. 3. febr. 21:36 UTC

Peļņas

These Stocks Are Today's Movers: Palantir, Pfizer, AMD, PayPal, Novo Nordisk, PepsiCo, Merck, and More -- Barrons.com

2026. g. 3. febr. 19:56 UTC

Peļņas

Pfizer Stock Falls After Solid Earnings. What's Troubling Wall Street. -- Barrons.com

2026. g. 3. febr. 19:46 UTC

Peļņas

These Stocks Are Today's Movers: Palantir, Pfizer, AMD, PayPal, Novo Nordisk, PepsiCo, Merck, and More -- Barrons.com

2026. g. 3. febr. 17:35 UTC

Peļņas

Pfizer Stock Falls After Solid Earnings. What's Troubling Wall Street. -- Barrons.com

2026. g. 3. febr. 17:30 UTC

Peļņas

These Stocks Are Today's Movers: Palantir, PayPal, Novo Nordisk, Pfizer, Merck, AMD, Gartner, and More -- Barrons.com

2026. g. 3. febr. 13:50 UTC

Peļņas

Pfizer Stock Falls After Solid Earnings. What's Troubling Wall Street. -- Barrons.com

2026. g. 3. febr. 13:06 UTC

Peļņas

Pfizer Stock Falls After Solid Earnings. What's Troubling Wall Street. -- Barrons.com

2026. g. 3. febr. 12:45 UTC

Peļņas

These Stocks Are Today's Movers: Palantir, PayPal, Teradyne, Tesla, Pfizer, AMD, Merck, and More -- Barrons.com

2026. g. 3. febr. 12:02 UTC

Peļņas

Pfizer Stock Falls After Solid Earnings. What's Troubling Wall Street. -- Barrons.com

2026. g. 3. febr. 11:48 UTC

Peļņas

Pfizer: About 20 Key Pivotal Study Starts Planned for 2026 >PFE

2026. g. 3. febr. 11:48 UTC

Peļņas

Pfizer: Enters 2026 With Clear Strategic Priorities, Growing Late-Stage Pipeline >PFE

2026. g. 3. febr. 11:47 UTC

Peļņas

Pfizer: Current Financial Guidance Doesn't Anticipate Any Stock Buybacks in 2026 >PFE

2026. g. 3. febr. 11:46 UTC

Peļņas

Pfizer Sees 2026 Adjusted R&D Expenses $10.5B-$11.5B >PFE

2026. g. 3. febr. 11:45 UTC

Peļņas

Pfizer Reaffirms 2026 Guidance >PFE

2026. g. 3. febr. 11:45 UTC

Peļņas

Pfizer 4Q Rev $17.56B >PFE

2026. g. 3. febr. 11:45 UTC

Peļņas

Pfizer Sees FY Adj EPS $2.80-Adj EPS $3.00 >PFE

2026. g. 3. febr. 11:45 UTC

Peļņas

Pfizer 4Q Adj EPS 66c >PFE

2026. g. 3. febr. 11:45 UTC

Peļņas

Pfizer 4Q Loss/Shr 29c >PFE

2026. g. 3. febr. 11:45 UTC

Peļņas

Pfizer 4Q Loss $1.65B >PFE

2026. g. 3. febr. 11:45 UTC

Peļņas

Pfizer Sees FY Rev $59.5B-$62.5B >PFE

2026. g. 3. febr. 10:41 UTC

Peļņas

These Stocks Are Today's Movers: Palantir, Teradyne, Tesla, AMD, NXP Semiconductors, DaVita, and More -- Barrons.com

Salīdzinājums

Cenas izmaiņa

Pfizer Prognoze

Cenas mērķis

By TipRanks

10.61% augšup

Prognoze 12 mēnešiem

Vidējais 29.5 USD  10.61%

Augstākais 36 USD

Zemākais 25 USD

Pamatojoties uz 23 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Pfizer  — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt

23 ratings

9

Pirkt

12

Turēt

2

Pārdot

Tehniskais rādītājs

By Trading Central

22.855 / 23.85Atbalsts un pretestība

Īstermiņā

Bullish Evidence

Vidējā termiņā

Bearish Evidence

Ilgtermiņā

Bearish Evidence

Noskaņojums

By Acuity

141 / 348 Rangs Veselības aprūpe

Ziņu noskaņojums

Liecība "Lāču" tendencei

Volatilitāte

Zem vidējā

Ziņu apjoms (RCV)

Zem vidējā

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

$

Par Pfizer

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE, as well as has strategic clinical collaboration with Acepodia Inc. for the development of antibody-cell conjugation-based cell therapies in autoimmune diseases. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
help-icon Live chat